Changes of hepatic tissue phospholipid peroxidation, malondialdehydes, and antioxidative enzyme activities in dogs with halothane inhalation.
To elucidate the pathogenesis of halothane-induced hepatopathy, the changes of hepatic tissue phospholipid peroxidation, malondialdehydes (MDAs), and antioxidative enzyme activities were examined in the portal vein arterialized dogs with halothane inhalation. In group A, which was given halothane inhalation under the hepatic blood flow volume less than 10% of pre-operation volume designated as a hypoxic condition, peroxidized phosphatidylcholine (PC), and free and protein-bound MDA levels significantly increased after inhalation. Although the level of protein bound MDA in group C, given hypoxic condition alone, also increased during the experimental period, the response of this was smaller than that in group A, suggesting that the halothane inhalation enhanced free radical generation under the hypoxic condition. In contrast, no significant changes of these levels were observed in groups B and D, both of which were supplied with sufficient hepatic oxygen as the normoxic condition. In addition, the significant negative correlations between hepatic oxygen supply and total or protein-bound MDA were observed in only halothane inhaled group. These findings suggested that the cause of halothane-induced hepatopathy is closely related to free radicals mainly generated from halothane anaerobic metabolism under the hypoxic condition.
Yamazoe
K
K
Department of Veterinary Surgery, Faculty of Agriculture, Yanagido, Gifu University, Japan.
Inaba
T
T
Bonkobara
M
M
Matsuki
N
N
Ono
K
K
Kudo
T
T
D000280:Administration, Inhalation; D000818:Animals; D004285:Dogs; D005979:Glutathione Peroxidase / Q000378:metabolism*; D006221:Halothane / Q000008:administration & dosage / Q000494:pharmacology*; D007700:Kinetics; D015227:Lipid Peroxidation / Q000187:drug effects*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008102:Liver Circulation; D008315:Malondialdehyde / Q000378:metabolism*; D010101:Oxygen Consumption / Q000187:drug effects; D010713:Phosphatidylcholines / Q000378:metabolism; D010714:Phosphatidylethanolamines / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D013482:Superoxide Dismutase / Q000378:metabolism*
D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D010743:Phospholipids; D008315:Malondialdehyde; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D006221:Halothane